O SlideShare utiliza cookies para otimizar a funcionalidade e o desempenho do site, assim como para apresentar publicidade mais relevante aos nossos usuários. Se você continuar a navegar o site, você aceita o uso de cookies. Leia nosso Contrato do Usuário e nossa Política de Privacidade.
O SlideShare utiliza cookies para otimizar a funcionalidade e o desempenho do site, assim como para apresentar publicidade mais relevante aos nossos usuários. Se você continuar a utilizar o site, você aceita o uso de cookies. Leia nossa Política de Privacidade e nosso Contrato do Usuário para obter mais detalhes.
Eigen strives to improve healthcare and quality of life through innovations in image-guided diagnosis and treatment of diseases.
Eigen provides reliable, competitive and quality products to satisfy our customers with optimum functionality relative to time and cost constraints. We dedicate ourselves to continuous improvement in performance, ease of installation, operation and maintenance.
Mission StatementEigen strives to improve healthcare and quality of life through innovations in image-guided diagnosis and treatment of diseases.
About Eigen• Privately-held company with ~$50M invested• Two 510(k) approvals – Plus one application pending• IP includes 25+ patents – issued, licensed and pending• 30+ scientific publications
About Eigen• Core Competencies – New product development R&D, engineering and commercialization – Medical imaging – Prostate cancer• 23 Employees – Medical imaging scientists, R&D, biomedical, manufacturing and electromechanical engineers
Market Opportunities• 1 in 6 men will get prostate cancer in his lifetime• Estimated new cases and deaths from prostate cancer in the U.S. in 2012: – New cases: 241,740 – Deaths: 28,170 (Source: National Cancer Institute)• Over 1 million biopsies performed the in U.S. annually
Market Opportunities• Prostate cancer minimally-invasive device surgical market in North America and Europe estimated to be: – $14.2B in 2011 – Expected to reach $24.9B by 2016 CAGR of 11.0% between 2011—2016 – Monitoring and visualization segment is leading market contributor ~38% share in 2011 (source: Transparency Market Research)
Market Opportunities• Prostate cancer therapies market expected to be worth $5 billion in U.S. by 2015
Product Portfolio• Urology applications – 3D image-guided biopsy system (Artemis) Provides accurate guidance using 3D ultrasound imaging Records precise prostate biopsy locations Aids in disease management Aids in early detection
Product Portfolio MRI TRUS Prostate• Radiology applications Lesion – MRI/TRUS fusion guidance • Uses MRI for diagnosis of prostate cancer • Provides accurate guidance to suspected lesions – Interventional cardiology
Products in Pipeline• Urology Applications • 3D image-guided therapy system • Upgrades on Artemis (2.1 and 3.0)• Radiology Applications • ProFuse • eiView Workstation • DSA 2000
Artemis Hardware Tracker Establishes andmaintains a frame of Arm reference between Positions devicepatient and 3D TRUS relative to a patient image Cradle Touchscreen Interfaces Artemis Monitor hardware with specific OEM probe
Artemis Workflow Scan Capture 3D scan Compute prostate boundaries Plan Load a plan or select sites in 3D volume Biopsy Maneuver arm to perform targeted biopsies Record sample Report core locations Review images Update or add pathological findings
Artemis Smart BiopsyTMHow an Artemis-assisted Smart Conventional SmartBiopsy compares with a Ultrasound Prostatetraditional Biopsy Biopsy BiopsyTM3D color real-time display -Mapping and planning -Accurate needle guidance -Biopsy recording & review -Modern imaging technology -Advanced diagnostic info -Provides baseline of prostate biopsy -dataTargeted repeat biopsies -